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Abstract
Background: The transcriptional regulator c-Myc is the most frequently deregulated oncogene in
human tumors. Targeted overexpression of this gene in mice results in distinct types of lung
adenocarcinomas. By using microarray technology, alterations in the expression of genes were
captured based on a female transgenic mouse model in which, indeed, c-Myc overexpression in
alveolar epithelium results in the development of bronchiolo-alveolar carcinoma (BAC) and
papillary adenocarcinoma (PLAC). In this study, we analyzed exclusively the promoters of induced
genes by different in silico methods in order to elucidate the c-Myc transcriptional regulatory
network.
Results: We analyzed the promoters of 361 transcriptionally induced genes with respect to c-Myc
binding sites and found 110 putative binding sites in 94 promoters. Furthermore, we analyzed the
flanking sequences (+/- 100 bp) around the 110 c-Myc binding sites and found Ap2, Zf5, Zic3, and
E2f binding sites to be overrepresented in these regions. Then, we analyzed the promoters of 361
induced genes with respect to binding sites of other transcription factors (TFs) which were
upregulated by c-Myc overexpression. We identified at least one binding site of at least one of these
TFs in 220 promoters, thus elucidating a potential transcription factor network. The analysis
correlated well with the significant overexpression of the TFs Atf2, Foxf1a, Smad4, Sox4, Sp3 and
Stat5a. Finally, we analyzed promoters of regulated genes which where apparently not regulated by
c-Myc or other c-Myc targeted TFs and identified overrepresented Oct1, Mzf1, Ppargamma, Plzf,
Ets, and HmgIY binding sites when compared against control promoter background.
Conclusion: Our in silico data suggest a model of a transcriptional regulatory network in which
different TFs act in concert upon c-Myc overexpression. We determined molecular rules for
transcriptional regulation to explain, in part, the carcinogenic effect seen in mice overexpressing
the c-Myc oncogene.
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Background
The proto-oncogene c-Myc is highly expressed in many
cancer types [1-3] and plays a critical role in regulating cell
growth, proliferation, loss of differentiation, and apopto-
sis [4]. In transgenic mice, targeted overexpression of Myc
has been shown to be sufficient to induce cancer [5-7]. In
our department, a transgenic mouse model was created
which overexpresses c-Myc. The c-Myc overexpression in
alveolar epithelium of these mice results in the develop-
ment of bronchiolo-alveolar carcinoma (BAC) and papil-
lary adenocarcinoma (PLAC). Life expectancies of c-Myc
transgenics range between 12–14 months.
The molecular mechanisms by which c-Myc functions to
effect tumorigenesis have been the subject of extensive
research in the past several decades. c-Myc is a transcrip-
tion factor, a basic helix-loop-helix leucine zipper protein
that dimerizes with Max to bind the DNA sequence 5'-
CACGTG-3', known as an E box, and activates transcrip-
tion [8]. Myc also represses transcription through interac-
tion with Miz-1 or through other elements at core
promoters [9]. Furthermore, Brenner et al. [10] suggested
that c-Myc may also repress transcription by recruitment
of a DNA methyl-transferase corepressor Dnmt3a. DNA
methylation is the most important epigenetic modifica-
tion in mammalian cells and is associated with transcrip-
tional repression. Nevertheless, the mechanisms of
transcriptional repression by c-Myc seem not to occur by
direct binding of c-Myc to the DNA sequence 5'-CACGTG-
3', known as an E box, and are not really well understood.
The pleiotropic effects of c-Myc on tumorigenesis are
thought to be mediated by its target genes, because tran-
scriptionally defective Myc alleles have diminished trans-
forming potential [11]. Furthermore, the domain that is
required for c-Myc DNA binding, the basic helix-loop-
helix zipper domain, is essential for its oncogenic trans-
formation, and c-Myc possesses an N-terminal transacti-
vation domain. Deletions or mutations in this domain
result in loss of c-Myc transformation [12]. The transcrip-
tional activation potential of c-Myc, however, does not
always correlate with its ability to transform rodent
fibroblast cells [13]. Several studies showed that muta-
tions in the Myc box II domain within c-Myc can abrogate
its transformation capacity without affecting c-Myc activa-
tion of reporter gene constructs [14,15]. These results
emphasized the complex and interrelated nature of c-Myc-
mediated transformation and highlighted the need to
identify specific factors that interact with functionally
important domains of the c-Myc oncoproteins.
Despite extensive research, the specific mechanisms by
which tumorigenesis are achieved are not well under-
stood. This is largely because a comprehensive list of bio-
logically relevant Myc target genes has not yet been
defined and such "transformation" associated genes
remain elusive [16]. In order to elucidate Myc targets
many different techniques have been employed, such as
microarray profiling, serial analysis of gene expression,
and chromatin immunoprecipitation [17-25]. To date, >
1,600 genes have been found to be Myc-responsive and
stored in the Myc target gene database [26,27], but only a
minority of the Myc-responsive genes have been impli-
cated as direct target genes. C-Myc seems to induce a reg-
ulatory gene network, which consists of direct and indirect
responses. The direct responses also seem to depend on
different other transcription factors which either cooper-
ate with or compete against c-Myc. Some of these tran-
scription factors have already been described in the
literature [28,29].
In this study, we report a genetic and bioinformatic
approach designed to identify regulatory gene networks
induced by overexpression of c-Myc in alveolar epithe-
lium of our female transgenic mouse model, resulting in
the development of bronchiolo-alveolar carcinoma (BAC)
and papillary adenocarcinoma (PLAC). Because the
mechanisms of transcriptional repression by c-Myc do not
occur by direct binding of c-Myc to E boxes, we restricted
our analysis to promoter sequences of induced genes in
which the potential c-Myc binding sites can be identified
in silico. Thus, we have identified potential direct target
genes of c-Myc and propose different transcription factors
which either cooperate with or compete against c-Myc.
Furthermore, we in silico describe different indirect mech-
anisms possibly participating in the Myc tumorigenic phe-
notype. Taken together, we suggest a model of a regulatory
gene network in which different TFs act in concert upon
overexpression of c-Myc in our transgenic mouse model.
Results
Analysis of high-density oligonucleotide microarray data
Global gene expression studies were done with lung tissue
stemming from a female mouse transgenic line overex-
pressing the c-Myc proto-oncogene. The complete data
have been deposited in NCBIs Gene Expression Omnibus
(GEO) [30] and are accessible through GEO Series acces-
sion number GSE10954. The quantitative changes in sig-
nificantly altered genes were investigated. For the
definition of "significantly altered", see the Methods sec-
tion. According to these criteria, transcription of 469
genes was induced and transcription of 8 genes was
repressed in 5 months old animals (data shown in Addi-
tional file 1). At this time point the tumor burden was
approximately 50%. It must be mentioned here that gene
expression profiling by microarrays does not provide
information about rates of transcription but measure
mRNA abundance which might have been modified by
processes such as reduced RNA degradation.BMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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Validation of microarray data by real time PCR
For the validation of microarray data, five different genes
were selected: Met (met proto-oncogene), Myct1 (myc tar-
get 1), Myc (myelocytomatosis oncogene), Pnliprp1 (pan-
creatic lipase related protein 1) and Pbk (PDZ binding
kinase). Expression of these genes was alternatively inves-
tigated with real time quantitative PCR using the LightCy-
cler®. Comparison of fold changes determined by
microarray analysis and real time PCR are shown in Figure
1. Statistical significant changes in microarray analysis are
indicated by a black diamond. Criteria for significance are
described in the methods section. Statistical significant
changes in real time PCR are marked with an asterisk,
which is based on a paired two-tailed student t-Test. The
results were considered significant when the p-value was
less than 0.05. As shown in Figure 1 there was basic agree-
ment between the two platforms. The fold changes of Met,
however, differ strongly between microarray analysis and
real time PCR. This phenomenon can be observed some-
times with the validation of microarray data by real time
PCR: microarray analysis shows strong up regulation
whereas PCR indicates a very low fold change like 1.5 or
less. Here, the reason might be the low average intensity
value of 40.01 combined with its high standard deviation
of 67.12% for Met in the microarray experiments of non-
transgenic animals. Notably, the average standard devia-
tion of all significantly regulated genes of this study
amounts 23.81%. Together with a high and stable average
intensity value of 480 combined with its low standard
deviation of 16.83% for Met in the microarray experi-
ments of c-myc-transgenic animals the corresponding fold
change appears higher than it might be in fact. Further-
more, we did not compare gene expression on identical
sequences. Hence, we can not exclude the possibility that
transcript expression differs on the basis of the different
sequences (primers and amplification products)
employed.
Promoter sequence analysis of genes induced by 
overexpression of c-Myc
A flowchart of our in silico strategy used to elucidate the
c-Myc regulatory network is depicted in Figure 2.
1) Analysis of promoters of 361 induced genes with respect to c-Myc 
binding sites
By using their RefSeq annotation, 361 promoter
sequences could be extracted from the UCSC Genome
Browser for the 469 upregulated genes. Furthermore, pro-
moters of 100 genes which were not regulated at all were
extracted (the list of non-regulated genes was prepared
after applying criteria according to the Methods section
and was included in Additional file 2). Both sequence sets
were analyzed using TRANSFAC® Professional rel. 8.3 inte-
grated tool MATCH®  by using the matrices
V$EBOX_Q6_01 (cut-off core similarity: 1.00, matrix sim-
ilarity: 0.99), V$MYC_Q2 (cut-off core similarity: 1.00,
matrix similarity: 0.99), and V$MYCMAX_B (cut-off core
similarity: 0.75, matrix similarity: 0.96). The results of
these analyses including positions and sequences of the
corresponding binding sites are given in Additional file 3.
Altogether, 110 different c-Myc binding sites were found
in 94 different promoters, which partly were recognized
by different matrices. Table 1 gives the 94 genes which are
putatively directly regulated by c-Myc and the correspond-
ing biological process they are involved in. In this table,
the 15 targets stored already in the Myc Target Database
are marked bold. Moreover, the number of c-Myc binding
sites identified in the promoter set including promoters of
induced genes was compared to the number of c-Myc
binding sites identified in the control promoter set. The
Validation of microarray data by real time PCR Figure 1
Validation of microarray data by real time PCR. Com-
parison of gene expression of selected genes determined by 
microarray analysis (black bars) and real time PCR (grey bars; 
LC: LightCycler®). Fold changes are shown on the y-axis. Sig-
nificant changes of gene expression are indicated either with 
a diamond for array analysis or with an asterisk for real time 
PCR.
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Flow chart of our in silico strategy used to elucidate the c- Myc regulatory network Figure 2
Flow chart of our in silico strategy used to elucidate 
the c-Myc regulatory network.
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Table 1: Putative direct c-Myc targets: biological processes
Probe Set ID Gene Symbol Gene Title Biological process
1420821_at Sgpp1 sphingosine-1-phosphate phosphatase 1 apoptosis
1428480_at Cdca8 cell division cycle associated 8 cell cycle
1435306_a_at Kif11 kinesin family member 11 cell cycle
1423903_at Pvr poliovirus receptor cell-cell adhesion
1422889_at Pcdh18 protocadherin 18 cell-cell adhesion
1427489_at Itga8 integrin alpha 8 cell-matrix adhesion
1419717_at Sema3e sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3E
development
1448595_a_at Bex1 brain expressed gene 1 development
1422198_a_at Shmt1 serine hydroxymethyltransferase 1 (soluble) amino acid metabolism
1418483_a_at Ggta1 glycoprotein galactosyltransferase alpha 1, 3 carbohydrate metabolism
1421879_at Mtmr1 myotubularin related protein 1 lipid metabolism
1426575_at Sgms1 sphingomyelin synthase 1 lipid metabolism
1445103_at Tmem23 Transmembrane protein 23 lipid metabolism
1417300_at Smpdl3b sphingomyelin phosphodiesterase, acid-like 3B lipid metabolism
1421957_a_at Pcyt1a phosphate cytidylyltransferase 1, choline, alpha isoform lipid metabolism
1422702_at Azin1 antizyme inhibitor 1 polyamine metabolism
1417190_at Pbef1 pre-B-cell colony-enhancing factor 1 NAD biosynthetic process
1423088_at Tmod3 tropomodulin 3 negative regulation of cell motility
1420847_a_at Fgfr2 fibroblast growth factor receptor 2 proliferation
1415691_at Dlg1 discs, large homolog 1 (Drosophila) proliferation
1422966_a_at Tfrc transferrin receptor proliferation
1420924_at Timp2 tissue inhibitor of metalloproteinase 2 proliferation
1420020_at Suz12 suppressor of zeste 12 homolog (Drosophila) proliferation
1416657_at Akt1 thymoma viral proto-oncogene 1 proliferation
1420852_a_at B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 
2
protein amino acid glycosylation
1426342_at Stt3b STT3, subunit of the oligosaccharyltransferase complex, 
homolog B (S. cerevisiae)
protein amino acid glycosylation
1425581_s_at Galnt7 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyltransferase 7
protein amino acid glycosylation
1415692_s_at Canx calnexin protein folding
1429502_at Stch stress 70 protein chaperone, microsome-associated, human 
homolog
protein folding
1427074_at Pcmtd2 protein-L-isoaspartate (D-aspartate) O-methyltransferase 
domain containing 2
protein modification
1426721_s_at Tiparp TCDD-inducible poly(ADP-ribose) polymerase protein modification
1439151_at Msrb3 methionine sulfoxide reductase B3 protein repair
1431361_at Prcp prolylcarboxypeptidase (angiotensinase C) proteolysis
1421857_at Adam17 a disintegrin and metallopeptidase domain 17 proteolysis
1422528_a_at Zfp36l1 zinc finger protein 36, C3H type-like 1 regulation of mRNA stability
1420975_at Baz1b bromodomain adjacent to zinc finger domain, 1B regulation of transcription, DNA-dependent
1421162_a_at Nfia nuclear factor I/A regulation of transcription, DNA-dependent
1423773_at Gpbp1 GC-rich promoter binding protein 1 regulation of transcription, DNA-dependent
1423441_at Tfb2m transcription factor B2, mitochondrial regulation of transcription, DNA-dependent
1422864_at Runx1 runt related transcription factor 1 regulation of transcription, DNA-dependent
1416018_at Dr1 down-regulator of transcription 1 regulation of transcription, DNA-dependent
1418280_at Klf6 Kruppel-like factor 6 regulation of transcription, DNA-dependent
1425465_a_at Senp2 SUMO/sentrin specific peptidase 2 regulation of transcription, DNA-dependent
1421908_a_at Tcf12 transcription factor 12 regulation of transcription, DNA-dependent
1434643_at Tbl1x transducin (beta)-like 1 X-linked regulation of transcription, DNA-dependent
1426531_at Zmynd11 zinc finger, MYND domain containing 11 regulation of transcription, DNA-dependent
1419976_s_at Nfatc3 nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 3
regulation of transcription, DNA-dependent
1432143_a_at Hbp1 high mobility group box transcription factor 1 regulation of transcription, DNA-dependent
1427418_a_at Hif1a hypoxia inducible factor 1, alpha subunit regulation of transcription, DNA-dependent
1421835_at Mtap7 microtubule-associated protein 7 response to osmotic stress
1415996_at Txnip thioredoxin interacting protein response to oxidative stress
1416467_at Ddx3x DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked RNA helicase activity
1415807_s_at Sfrs2 splicing factor, arginine/serine-rich 2 (SC-35) RNA splicingBMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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corresponding calculated fold occurrences of binding sites
and the significance (p-value) of the occurrence values are
given in Table 2. The fold occurrences describe the
number of c-Myc binding sites detected as a ratio with
regard to the number of gene promoters analyzed. Here,
the fold occurrence of the non-regulated gene promoters
is set to 1. For all matrices used the fold occurrences of the
c-Myc binding sites of the analyzed promoters in total are
increased in comparison to the fold occurrences of the c-
Myc binding sites of the control gene promoters in total.
Furthermore, the significance of the occurrence values is
high. This result indicates direct regulation by c-Myc of
many of the genes analyzed.
1425625_at Il13ra1 interleukin 13 receptor, alpha 1 signal transduction
1426892_at Utrn utrophin signal transduction
1433706_a_at Ptplad1 protein tyrosine phosphatase-like A domain containing 1 signal transduction
1424947_at Dync1li1 dynein cytoplasmic 1 light intermediate chain 1 signal transduction
1425538_x_at Ceacam1 CEA-related cell adhesion molecule 1 signal transduction
1420918_at Sgk3 serum/glucocorticoid regulated kinase 3 signal transduction
1437295_at Pkn2 protein kinase N2 signal transduction
1416504_at Ulk1 Unc-51 like kinase 1 (C. elegans) signal transduction
1418489_a_at Calcrl calcitonin receptor-like signal transduction
1421239_at Il6st interleukin 6 signal transducer signal transduction
1420814_at Gdi2 guanosine diphosphate (GDP) dissociation inhibitor 2 signal transduction
1420696_at Sema3c sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C
signal transduction
1418022_at Narg1 NMDA receptor-regulated gene 1 transcription
1420307_a_at Pitpnb phosphatidylinositol transfer protein, beta transport
1419970_at Slc35a5 solute carrier family 35, member A5 transport carbohydrate
1421839_at Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 transport cholesterol
1417622_at Slc12a2 solute carrier family 12, member 2 transport ion
1418257_at Slc12a7 solute carrier family 12, member 7 transport ion
1416832_at Slc39a8 solute carrier family 39 (metal ion transporter), member 8 transport metal ion
1426712_at Slc6a15 solute carrier family 6 (neurotransmitter transporter), member 
15
transport neurotransmitter
1421641_at Slc6a2 solute carrier family 6 (neurotransmitter transporter, 
noradrenalin), member 2
transport neurotransmitter
1421167_at Atp11a ATPase, class VI, type 11A transport phospholipid
1423597_at Atp8a1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, 
member 1
transport phospholipid
1428065_at Slc44a2 solute carrier family 44, member 2 transport protein
1416375_at Ap3m1 adaptor-related protein complex 3, mu 1 subunit transport protein
1436508_at 2410014A08Rik RIKEN cDNA 2410014A08 gene transport protein
1416189_a_at Sec61a1 Sec61 alpha 1 subunit (S. cerevisiae) transport protein
1426775_s_at Scamp1 secretory carrier membrane protein 1 transport protein
1420867_at Tmed2 transmembrane emp24 domain trafficking protein 2 transport protein
1421955_a_at Nedd4 neural precursor cell expressed, developmentally down-regulted 
gene 4
ubiquitin cycle
1416680_at Ube3a ubiquitin protein ligase E3A ubiquitin cycle
1426495_at 2410042D21Rik RIKEN cDNA 2410042D21 gene ?
1419152_at 2810417H13Rik RIKEN cDNA 2810417H13 gene ?
1421603_a_at Ceacam2 CEA-related cell adhesion molecule 2 ?
1417821_at D17H6S56E-5 DNA segment, Chr 17, human D6S56E 5 ?
1423557_at Ifngr2 interferon gamma receptor 2 ?
1421064_at Mpp5 membrane protein, palmitoylated 5 (MAGUK p55 subfamily 
member 5)
?
1421814_at Msn moesin ?
1423479_at Nol11 nucleolar protein 11 ?
1426806_at Obfc2a oligonucleotide/oligosaccharide-binding fold containing 2A ?
1424778_at Reep3 receptor accessory protein 3 ?
The table gives the 94 genes which are putatively directly regulated by c-Myc and the corresponding biological processes they are involved in. In this 
table, the 15 targets stored already in the Myc Target Database are marked bold.
Table 1: Putative direct c-Myc targets: biological processes (Continued)BMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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2) Analysis of flanking sequences (+/- 100 bp) around the 110 c-Myc 
binding sites
For this analysis, we extracted the 110 c-Myc binding sites
including the flanking sequences (100 bp flanking the 5
bp core sequence to both sides (= 205 bp)). We further
randomly extracted the same number of 205 bp sequences
from the control promoters which were not regulated at
all (the list of 205 bp sequences of non-regulated genes
was included in Additional file 4). Both sequence sets
were analyzed using TRANSFAC® Professional rel. 8.3 inte-
grated tool MATCH®  by using the matrix profile
"vertebrates_minSUM_highQual". An extract of the
results of these analyses including the numbers of tran-
scription factor binding sites in the corresponding pro-
moter sets, the following fold occurrence of a given TF,
and the significance (p-value) of the occurrence values are
listed in Table 3. The complete result of this analysis is
given in Additional file 5. According to Table 3, the puta-
tive c-Myc binding sites in the 110 analyzed sequences
have been identified by six different matrices included in
the profile used (V$MYC_Q2, V$MYCMAX_01,
V$MYCMAX_02, V$MYCMAX_B, V$MAX_01, and
EBOX_Q6_01). The 110 different putative c-Myc binding
sites were recognized partly by different matrices. As
expected the significance of the occurrence values for each
c-Myc matrice is high, respectively. Furthermore, the
number of hits of different matrices for the transcription
factors E2F, AP2, ZF5, and ZIC3 clearly shows a highly sig-
nificant overrepresentation in comparison to control
sequences which contain nearly no c-Myc binding sites.
This might mean that these TFs bind in the nearest neigh-
borhood to c-Myc in order to either cooperate with or
compete against c-Myc. The distribution of these TFs
around the c-Myc binding sites is shown in Figure 3. Here,
the diagrams show that AP2 and ZIC3 do not or nearly not
bind to the same site as c-Myc does, whereas E2F and ZF5
in some cases seem to bind to the same site as c-Myc.
Table 3: Analysis of flanking sequences (+/- 100 bp) around the 110 c-Myc binding sites
Matrix Hits in sequences (205 bp) of induced 
promoters
Hits in sequences (205 bp) of control 
promoters
Fold-Occurrence P-Wert
V$MYC_Q2 96 7 13.71 1.04731E-98
V$MYCMAX_01 16 4 4.00 2.00649E-06
V$MYCMAX_02 10 1 10.00 7.25446E-08
V$MYCMAX_B 18 2 9.00 1.73837E-12
V$MAX_01 34 6 5.67 4.50618E-17
V$EBOX_Q6_01 25 2 12.50 2.36615E-20
V$E2F_Q2 50 21 2.38 2.08371E-10
V$E2F1_Q3 22 7 3.14 1.12327E-06
V$E2F1_Q3_01 11 3 3.67 0.000171353
V$E2F1_Q6 11 5 2.20 0.007294131
V$AP2_Q6 17 7 2.43 0.000392586
V$AP2_Q6_01 14 5 2.80 0.000339388
V$AP2ALPHA_03 30 8 3.75 1.41269E-10
V$AP2GAMMA_01 21 2 10.50 1.04239E-15
V$ZF5_B 85 37 2.30 7.71777E-21
V$ZIC3_01 22 10 2.20 0.000213134
The TRANSFAC identifier of the respective matrix, the number of hits in the 110 different sequences (205 bp) of induced gene promoters, the 
number of hits in the 110 different sequences (205 bp) of control (non-regulated) gene promoters, and the corresponding fold occurrences are 
given in this table. The occurrence value of the respective binding site in the promoters of control genes is set to 1. Significance of the 
representation value of binding sites in flanking sequences (+/- 100 bp) around the 110 c-Myc binding sites in the promoters of induced genes is 
measured by the p-value derived from the binomial distribution.
Table 2: Fold occurrences of c-Myc binding sites in the promoters of induced genes.
Matrices applied in the analysis of 
promoter sequences of 361 c-Myc-
regulated genes
Number of binding sites found in 
all promoter sequences
Fold occurrence of binding sites Significance (p-value)
V$EBOX_Q6_01 28 1.55 0.006492733
V$MYC_Q2 115 1.10 0.022316242
V$MYCMAX_B 52 1.31 0.008330239
The occurrence value of c-Myc binding sites in the promoters of control genes is set to 1. Significance of the representation value of c-Myc binding 
sites in the promoters of induced genes is measured by the p-value derived from the binomial distribution.BMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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3) Analysis of promoters of 361 induced genes with respect to 
binding sites of TFs which were transcriptionally induced by 
overexpression of c-Myc
According to GeneOntology 36 of 477 deregulated genes
possess transcription factor activity or transcription regu-
lator activity (Additional file 6). In the database TRANS-
FAC® Professional rel. 8.3, however, positional weight
matrices are available only for the 6 transcription factors
Atf2, Foxf1a, Smad4, Sox4, Sp3, and Stat5a, which were
upregulated by overexpression of c-Myc.
Next, we analyzed the 361 promoter sequences out of 469
upregulated genes which are available in the UCSC
Genome Browser, using the TRANSFAC® Professional rel.
8.3 integrated tool MATCH® by applying the matrices
V$CREBATF_Q6 (cut-off core similarity: 1.00, matrix sim-
ilarity: 0.98), V$HFH8_01 (cut-off core similarity: 1.00,
matrix similarity: 0.97), V$SMAD-4 (cut-off core similar-
ity: 0.95, matrix similarity: 0.88), V$SOX_Q6 (cut-off core
similarity: 1.00, matrix similarity: 0.88), V$STAT5A_03
(cut-off core similarity: 1.00, matrix similarity: 1.00),
V$STAT5A_04 (cut-off core similarity: 1.00, matrix simi-
larity: 1.00), V$STAT5A_01 (cut-off core similarity: 1.00,
matrix similarity: 0.98), V$STAT5A_02 (cut-off core simi-
larity: 1.00, matrix similarity: 0.83), and V$SP3_Q3 (cut-
off core similarity: 0.90, matrix similarity: 0.91). The
results of this analysis including positions and sequences
of the corresponding binding sites are given in Additional
file 7. Altogether, 368 putative binding sites were found in
220 different promoters. 115 binding sites for Atf2
(V$CREBATF_Q6) in 73 different promoters were identi-
fied, 44 binding sites for Foxf1a (V$HFH8_01) in 42 dif-
ferent promoters, 53 binding sites for Smad4
(V$SMAD_4) in 47 different promoters, 33 binding sites
for Sox4 (V$SOX_Q6) in 31 different promoters, 82 bind-
ing sites for Stat5a (V$STAT5A_01, V$STAT5A_02,
V$STAT5A_03, V$STAT5A_04) in 71 different promoters,
and 41 binding sites for SP3 (V$SP3_Q3) in 39 different
promoters. They are listed in Additional file 8. 46 out of
the 220 promoters possessing a binding site of a transcrip-
tion factor whose transcription was induced by c-Myc pos-
sess also a c-Myc binding site (see Additional file 9).
Distribution of overrepresented TFs around the c-Myc binding sites (+/- 100 bp) Figure 3
Distribution of overrepresented TFs around the c-Myc binding sites (+/- 100 bp). Localization of binding sites (BSs) 
for the respective transcription factor (TF) within the flanking sequences around the c-Myc BSs. The position in bp within the 
whole extracted and analyzed sequence is given on the x-axis. The core sequences of c-Myc BSs are located at bp 100 to 105 
and are marked by the green lines. The number of identified BSs are shown on the y-axis.
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4) Analysis of promoters of induced genes – without any c-Myc 
binding sites and without any binding sites of TFs which were induced 
by c-Myc – with respect to binding sites of other TFs
The 96 promoters of genes induced by overexpression of
c-Myc which possess neither a putative c-Myc binding site
nor a binding site of a transcription factor which was tran-
scriptionally induced by c-Myc were analyzed using
TRANSFAC® Professional rel. 8.3 integrated tool MATCH®
by applying the matrix profile
"vertebrates_minSUM_highQual". We further performed
the same analysis using control promoters which were not
regulated at all (Additional file 2). An extract of the results
of these analyses including the numbers of transcription
factor binding sites in the corresponding promoter sets
and the resulting fold occurrence of a given TF are listed in
Table 4. According to this table, the different matrices for
the transcription factors Oct1, Mzf1, Pparg, Plzf, Ets, and
HmgIY provide more than 30 hits. This table clearly
shows an overrepresentation in comparison to control
sequences. We found 36 putative Oct1 binding sites in 27
promoters, 37 putative Mzf1 binding sites in 24 promot-
ers, 131 putative Pparg binding sites in 57 promoters, 47
putative Plzf binding sites in 37 promoters, 42 putative
Ets binding sites in 25 promoters, and 46 putative HmgIY
Table 4: Analysis of promoters of induced genes – without any c-Myc binding sites and without any binding sites of TFs which were 
induced by c-Myc – with respect to binding sites of other TFs
Matrix Number of binding sites in 
promoters of 96 induced 
genes
Number of binding sites in 
promoters of 100 non-
regulated genes
Fold occurrence Significance (p-value)
V$HNF4_01 6 1 6.25 0.000375206
V$CREL_01 10 2 5.21 2.03259E-05
V$NFKAPPAB65_01 5 1 5.21 0.002449147
V$NFKB_Q6_01 5 1 5.21 0.002449147
V$PPARG_01 11 4 2.86 0.001151136
V$NFKB_C 5 2 2.6 0.031112513
V$P53_DECAMER_Q2 10 4 2.6 0.003533721
V$COUPTF_Q6 12 5 2.5 0.002051505
V$ELF1_Q6 12 5 2.5 0.002051505
V$IRF_Q6_01 26 11 2.46 7.01224E-06
V$P53_02 7 3 2.43 0.017329258
V$NF1_Q6 18 8 2.34 0.000369053
V$PPAR_DR1_Q2 11 5 2.29 0.005502861
V$CEBPGAMMA_Q6 19 9 2.2 0.000532298
V$AP1_Q4 10 5 2.08 0.013373232
V$NF1_Q6_01 10 5 2.08 0.013373232
V$E2F1DP2_01 8 4 2.08 0.023927388
V$E2F4DP2_01 8 4 2.08 0.023927388
V$AP1_Q2 11 6 1.91 0.016631957
V$AR_01 11 6 1.91 0.016631957
V$OCT1_03 36 21 1.79 9.18715E-05
V$HIC1_03 12 7 1.79 0.019471252
V$HNF4_01_B 12 7 1.79 0.019471252
V$PLZF_02 47 28 1.75 6.68834E-06
V$ETS_Q6 20 12 1.74 0.005001828
V$FREAC4_01 10 6 1.74 0.033328378
V$XFD1_01 10 6 1.74 0.033328378
V$OCT1_06 13 8 1.69 0.021905095
V$ETS_Q4 22 14 1.64 0.006219504
V$CAAT_01 14 9 1.62 0.023973145
V$CDPCR1_01 12 8 1.56 0.038985854
V$E47_02 18 12 1.56 0.017018836
V$P53_01 6 4 1.56 0.096354785
V$STAT_Q6 12 8 1.56 0.038985854
V$MZF1_02 37 25 1.54 0.001169513
V$PPARG_02 79 64 1.52 0.001699828
V$HMGIY_Q3 46 32 1.5 0.000431589
The TRANSFAC identifier of the respective matrix, the number of hits in the 96 induced gene promoters, the number of hits in the 100 non-
regulated control gene promoters, and the corresponding fold occurrences are given in this table. The occurrence value of the respective binding 
site in the promoters of control genes is set to 1. Significance of the representation value of TF binding sites in the promoters is measured by the p-
value derived from the binomial distribution.BMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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binding sites in 30 promoters. They are listed in Addi-
tional file 8. A summary of all results is depicted in Figure
4.
Discussion
Transcription profiling studies have identified many tar-
get genes activated or repressed by c-Myc in various ani-
mal and human cells or cell lines. The number of
experimentally validated c-Myc targets is rapidly expand-
ing thanks to the use of high-throughput methods [19,31-
33]. Two recent studies suggest that the potential list of c-
Myc targets could be much larger than what was previ-
ously anticipated [22,31]. Moreover, Chen et al. [32] sug-
gest the existence of a significant tissue-specific
component in the response of many c-Myc target genes.
Gene expression studies alone, however, cannot discrimi-
nate between direct and indirect targets of c-Myc action,
although network-based interference of direct action has
been proposed [31]. Furthermore, gene expression studies
alone can identify neither transcription factor activations
or repressions on the protein level nor transcriptional
cooperation and competition of different transcription
factors involved in the corresponding regulatory network.
Analysis of promoters of regulated genes resulting from
gene expression studies, however, may provide indica-
tions in these directions.
Thus, using positional weight matrices (PWMs), which is
the most widely used method for recognition of transcrip-
tion factor binding sites [34,35], we analyzed promoters
of genes which were induced by overexpression of c-Myc
in alveolar epithelium of our female transgenic mouse
Coordinate events which resulted in gene regulation in response to c-Myc overexpression Figure 4
Coordinate events which resulted in gene regulation in response to c-Myc overexpression. 1) c-Myc putatively 
binds to 110 binding sites in 94 different promoters of induced genes. Binding sites (BSs) of four different transcription factors 
(TFs) have been shown to be overrepresented in the direct neighborhood of c-Myc binding sites. They either cooperate with 
or compete againstc-Myc. 2) Some of the genes induced by c-Myc overexpression code for transcription factors. These tran-
scription factors constitute the basis of a regulatory gene network that again influences the expression of different genes. 
Taken collectively, 220 different promoters of induced genes possess binding sites for those induced transcription factors, 
matrices of which areavailable. 3) Other transcription factors which could be part of the c-Myc regulatory gene network are 
those which might be activated on the protein level through the overexpression of c-Myc.
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model resulting in the development of bronchiolo-alveo-
lar carcinoma (BAC) and papillary adenocarcinoma
(PLAC), in order to elucidate the c-Myc transcriptional
regulatory network consisting of direct and indirect mech-
anisms possibly participating in the Myc tumorigenic phe-
notype. We wish to point out that the c-Myc
transcriptional regulatory network analyzed in other tis-
sues might be different from the network described in this
study. Indeed, an analysis of 89 genes whose promoters
(1000 bp upstream of the TSS) possess at least one exper-
imentally determined high-quality Myc binding locus on
human P493 B cells [29] provided no overlap with pro-
moters of genes in mouse lung adenocarcinoma reported
in the present study.
By applying three different weight matrices for recogni-
tion of c-Myc binding sites, we predicted 94 putative c-
Myc targets among the genes presented on Affymetrix
platform GeneChip® Mouse Genome 430 2.0. This list
contains 15 targets stored in the Myc Target Database,
whereas 79 genes are putative novel targets. Whether they
are real targets remains to be elucidated. The functional
categories of these 94 putative c-Myc targets revealed that
various cellular processes like transcriptional regulation,
protein modification and transport, cell cycle control/pro-
liferation, metabolism, and signal transduction are puta-
tively directly regulated by c-Myc. These findings correlate
well with expectations based on the biology of c-Myc.
In higher organisms transcription factors usually operate
in combination with other transcription factors bound in
direct neighborhood in promoter sequences to influence
gene transcription. Up to now, less is known about tran-
scription factors (TFs) collaborating with c-Myc. Previ-
ously, Elkon et al. [36] reported in silico identified
transcriptional regulators associated with c-Myc activity in
human Burkitt's lymphoma cells and this included over-
representation of binding sites of the transcription factors
ETF, SP1, Nrf-1, NF-Y, CREB, Egr-1, Elk-1, E2F and AhR/
Arnt in c-Myc target genes. The extracted and analyzed
promoters spanned 1000 bp upstream to 200 bp down-
stream of the transcription start sites of the corresponding
genes.
In the present study, we analyzed exclusively the flanking
sequences around the in silico identified c-Myc binding
sites by use of all available positional weight matrices in
the TRANSFAC database. Especially binding sites of the
transcription factors E2F, AP2, ZF5, and ZIC3 were found
to be significantly enriched from 2.2- to 10-fold over con-
trol promoter background. The poor concordance of our
results and those of Elkon et al. [36] might be due to dif-
ferent reasons: We analyzed different species, different tis-
sues, and different lengths of analyzed sequences and
therefore, possibly different distances from c-Myc binding
sites.
Notably, both studies identified E2F to be a transcrip-
tional regulator associated with c-Myc. Like c-Myc, E2F
also controls cell cycle progression and DNA replication
[37]. Thus, deregulation of c-Myc could potentially lead to
uncontrolled cell cycle progression through a functional
link with E2F, as proposed also by Zeller et al. [29]. The
authors supposed that high c-Myc expression leads to
increased E2F activity by upregulating genes involved in
cell cycle control. The cooperative binding of Myc and E2F
followed by transcriptional activation of key downstream
targets leads to an increase in DNA replication and cell
cycle progression (Figure 5). Here, by using four different
matrices for E2F, we found E2F binding sites in the direct
neighborhood of c-Myc binding sites (maximum distance
from c-Myc binding sites was 100 bps) in 37 sequences
out of 110 sequences possessing a c-Myc binding site.
Depending on the matrix used, they are 2.2- to 3.7-fold
enriched over the control promoter background. Further-
more, the network relationships between c-Myc and E2F
are also obvious through the identification of functional
E2F binding sites in the c-Myc [38] and in the E2F pro-
moter [39] as well as the identification of E2F as a c-Myc
target gene [26].
By using four different matrices for AP2, we also found
AP2 binding sites in the direct neighborhood of c-Myc
binding sites in 32 sequences out of 110 sequences pos-
sessing a c-Myc binding site. Depending on the matrix
applied, they are 2.4- to 10.5-fold enriched over the con-
trol promoter background. In 2006, Zeller et al. already
identified AP2 to be significantly enriched in cis-regula-
tory modules with c-Myc [29]. The AP2 family of tran-
scription factors plays a broad range of roles in cell
growth, tissue morphogenesis, and cancers. One of the
mechanisms by which the AP2 family fulfills their roles is
to activate or suppress various downstream target genes at
transcriptional levels. A number of studies demonstrated
that AP2-interacting proteins can affect the transcription
of AP2 downstream targets by modulating the transcrip-
tional activity of AP2. In fact, several AP2-interacting part-
ners have been identified, such as YY1, RB, and c-Myc
[28,40,41]. Thus, AP2 is a known c-Myc partner. In 1995,
Gaubatz et al. [28] showed that AP2 acts as an inhibitor of
Myc-mediated transactivation, a function that is mediated
both by competition of AP2 with binding of Myc or Max
and by direct protein-protein interaction of AP2 with the
BR/HLH/LZ domain of the Myc protein. Here, in the pro-
moters of which both binding sites – c-Myc and AP2 –
were found in the direct neighborhood, the overrepre-
sented transcription factor c-Myc might have induced the
corresponding gene transcription, whereas under normalBMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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Putative direct actions of c-Myc in part in cooperation or competition with other transcription factors Figure 5
Putative direct actions of c-Myc in part in cooperation or competition with other transcription factors.
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conditions AP2 might be able to inhibit this transactiva-
tion (Figure 5).
We also found ZF5 binding sites in the direct neighbor-
hood of c-Myc binding sites in 41 sequences out of 110
sequences possessing a c-Myc binding site. They are 2.3-
fold enriched over the control promoter background. ZF5
is a ubiquitously expressed protein originally identified by
its ability to bind and repress the murine c-Myc promoter
[42]. It contains an N-terminal POZ domain, which is a
conserved protein-protein interface that recruits cofactors
to modulate transcription [43]. ZF5 mediates both tran-
scriptional activation and repression of cellular and viral
promoters [42-44]. Here, in the promoters of which both
binding sites – c-Myc and ZF5 – were found in the direct
neighborhood, the overrepresented transcription factor c-
Myc might have induced the corresponding gene tran-
scription, whereas under normal conditions ZF5 might be
able to competitively inhibit this transactivation and fur-
ther inhibit the transcription of the c-Myc gene (Figure 5).
Furthermore, we found ZIC3 binding sites in the direct
neighborhood of c-Myc binding sites in 19 sequences out
of 110 sequences possessing a c-Myc binding site. They are
2.2-fold enriched over the control promoter background.
ZIC3 is a developmental specific zinc finger transcription
factor defining early embryo patterning [45]. Although
Zic3 expression has been implicated in embryonic devel-
opment, however, a detailed understanding is still miss-
ing of what regulates Zic3 expression and what the
downstream effectors of Zic3 are. Until now, there is no
indication of connectivity of Zic3 and c-Myc, with one
exception: in 2006, Zeller et al. found that the Zic3 bind-
ing motifs are significantly enriched in c-Myc-repressed
genes after a genome-wide characterization of direct c-
Myc binding targets in a model of human B lymphoid
tumor using ChiP coupled with pair-end ditag sequencing
analysis (ChiP-PET). Here, however, we found Zic3 bind-
ing motifs to be significantly enriched in c-Myc-induced
genes after overexpression of c-Myc in alveolar epithelium
of our female transgenic mouse model (Figure 5). To elu-
cidate the biological significance of this observation fur-
ther studies are necessary.
As mentioned above, gene expression studies alone can-
not discriminate between direct and indirect targets of c-
Myc action. Nevertheless, with overexpression of c-Myc in
alveolar epithelium of our female transgenic mouse
model resulting in the development of bronchiolo-alveo-
lar carcinoma (BAC) and papillary adenocarcinoma
(PLAC) 36 of 477 deregulated genes possess transcription
factor activity or transcription regulator activity. These
transcription factors mediate the indirect actions of c-Myc.
By using the corresponding available Positional Weight
Matrices from TRANSFAC (Atf2, Foxf1a, Smad4, Sox4,
Sp3, and Stat5a) for the analysis of the 477 deregulated
genes, many putative indirect targets of c-Myc action
could be identified. In 73 promoters at least one binding
site for ATF2 has been identified. ATF2 belongs to the
basic region leucine zipper (bZIP) family of transcription
factors and is an important member of activating protein
1 (AP-1) [46]. ATF2 functions either as a homodimer or as
a heterodimer with other members of the ATF family as
well as other bZIP proteins, to bind to specific DNA
sequences and activate gene expression. One major role of
ATF2 is to regulate the response of cells to stress signals
[47,48]. Furthermore, in 2001, Miethe J et al. [49] identi-
fied a crosstalk between Myc and activating transcription
factor 2 (ATF2): Myc prolongs the half-life of ATF2 and
causes increased phosphorylation of ATF2 at sites that
have been shown to be crucial for the regulation of ATF2
activity [49]. Thus, ATF2 is activated by c-Myc on the pro-
tein level. Here, we show a novel mechanism for gene acti-
vation by c-Myc: the transcriptional activation of the
transcription factor ATF2, which in turn putatively acti-
vates the transcription of 36 genes (Figure 6). Addition-
ally, Tamura et al. also demonstrated an interaction
between ATF2 and c-Myc in rat fibroblasts by affinity
chromatography and co-immunoprecipitation [50].
The members of the forkhead box (Fox) family of tran-
scription factors play important roles in regulating tran-
scription of genes involved in cellular proliferation,
differentiation, and metabolic homeostasis [51]. Foxf1
RNA is expressed at mesenchymal-epithelial interfaces
involved in lung and gut morphogenesis [52]. In the adult
mouse, Foxf1 RNA is detected in smooth muscle layers of
pulmonary bronchioles, lamina propria of the stomach
and the intestine, and in alveolar endothelial cells. Foxf1
is further essential for normal lung repair and endothelial
cell survival in response to pulmonary cell injury [53].
Here, we demonstrated transcriptional activation of the
Foxf1 gene by overexpression of c-Myc and thus an indi-
rect c-Myc action (Figure 6). Foxf1 putatively activates the
transcription of 42 genes.
Negative regulation of c-Myc expression by TGF-β is well
established and is a key mechanism through which TGF-β
causes G1 arrest and inhibition of cell proliferation in epi-
thelial cells. Three studies identified the TIE sequence in
the c-Myc promoter as mediating the TGF-β effect on c-
Myc expression. A complex of Smad3-Smad4, E2F4/5,
DP1, and p107 binds to the TIE in response to TGF-β to
inhibit transcription of c-Myc [54]. This Smad-dependent
repression of c-Myc expression was previously the only
known function of Smad4 in the regulation of c- Myc.
Data presented by Lim SK and Hoffmann FM [55] provide
evidence that Smad4 can also function as a positive regu-
lator of c- Myc expression in the absence of TGF-β signal-
ing. Here, in turn, we identified the ability of c-Myc to actBMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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Putative indirect actions of c-Myc, mediated by transcription factors induced by the overexpression of c-Myc Figure 6
Putative indirect actions of c-Myc, mediated by transcription factors induced by the overexpression of c-Myc.
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as a positive regulator of Smad4 expression (indirect or
direct). Smad4 again mediates the indirect effects of c-Myc
(Figure 6).
The SOX4 gene is highly expressed in human breast cancer
cell lines, colon cancer cell lines, hepatocarcinoma,
medulloblastomas, and adenoid cystic carcinomas [56-
58]. SOX-4 was also shown to be highly and differentially
expressed in a substantial fraction of small-cell lung carci-
noma (SCLC) samples and in a pool of primary lung ade-
nocarcinoma samples, with very low levels of expression
in a number of normal essential tissues. Notably, evidence
has been presented to suggest that SOX-4 may be involved
in tumorigenesis [59,60]. Here, we identified the ability of
c-Myc to act as an indirect positive regulator of SOX-4
expression. SOX-4 again mediates the indirect effects of c-
Myc (Figure 6).
Sp3 is a ubiquitous transcription factor closely related to
Sp1 and contains activation and inhibitory domains. It
can act as an activator or repressor of transcription
[61,62]. In 2004, the results of Abdelrahim M et al.
showed that Sp3 plays an important role in cell cycle pro-
gression of pancreatic cancer cells [63]. STAT5A is a tran-
scription factor that mediates cytokine and hormone
signals. Its constitutive activation has been observed in
several human cancers, and it is oncogenic in cell culture
models and transgenic animals [64]. Here, we identified
the ability of c-Myc to act as an indirect positive regulator
of SP3 and STAT5A expression. SP3 and STAT5A again
mediate the indirect effects of c-Myc (Figure 6).
General analysis of the promoters which do not contain
any putative c-Myc binding site nor any putative binding
site of transcription factors (TFs) being transcriptionally
induced by overexpression of c-Myc resulted in the obser-
vation that some TF binding sites are overrepresented
against the control promoter background. These are bind-
ing sites of the TFs: OCT1, MZF1, PPARg, PLZF, ETS, and
HMGIY (Figure 7).
Some of them are worth mentioning, because they seem
in part to mediate the carcinogenic effect seen in mice
after overexpression of the c-Myc oncogene: Oct1 modu-
lates the activity of genes important for the cellular
response to stress [65]. Although adipose tissue has been
recognized as a principal site of PPAR gamma expression,
it is now known that PPAR gamma is expressed in many
other types of tissues and cells. It has often been men-
tioned in the context of cancer: its ligand activation has
Putative indirect c-Myc actions, mediated by transcription factors regulated by overexpression of c-Myc on the protein level or  mediated by as yet unknown mechanisms Figure 7
Putative indirect c-Myc actions, mediated by transcription factors regulated by overexpression of c-Myc on the 
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been shown to be involved in promotion or regression of
colon tumors [66,67]. Furthermore, activation of PPAR
gamma agonists capable of modestly inducing apoptosis
has also been documented in a variety of tumor types
[68]. Notably, Yamakawa-Karakida N et al. (2002) pro-
vided the first evidence of the linkage between PPAR
gamma-mediated apoptosis and downregulation of c-Myc
gene expression [69].
PLZF is known to be a transcriptional repressor which is
associated with suppression of cellular proliferation.
McConnell MJ et al. (2003) showed that PLZF expression
maintains a cell in a quiescent state by repressing c-Myc
expression and preventing cell cycle progression [70].
They suggested that loss of this suppression would have
serious consequences for cell growth control and that
growth suppression mediated by PLZF can be reversed by
enforced expression of c-Myc. Here, through the overex-
pression of c-Myc, we found 37 putative target genes for
PLZF. They are, however, transcriptionally induced, which
might be the reversed effect mentioned by McConnell MJ
et al. [70]. Under normal conditions, these genes would
be transcriptionally repressed by PLZF. Loss of this repres-
sion might play a role in the development of the tumori-
genic phenotype of c-Myc.
HMGIY has been shown to be a direct c-Myc target gene
[71]. Some studies indicate an important role for HMGIY
proteins in regulating gene expression [72]. Histon H1-
mediated repression of transcription is reduced by
HMGIY [73]. Like c-Myc, expression of HMGIY also corre-
lates with rapidly proliferating mammalian tissues as well
as neoplastic transformation [74] and, moreover, a higher
residence time in heterochromatin and chromosomes,
compared with euchromatic regions, correlates with an
increased phosphorylation level of HMGIY [75].
The human Ets gene family includes 25 genes that code
for transcription factors involved in the control of various
aspects of cell proliferation, differentiation, and develop-
ment. Ets domain transcription factors have been impli-
cated in development of various forms of leukemias and
solid tumors. It has been well established that their func-
tion can be controlled by phosphorylation-mediated
effects on DNA binding. Phosphorylation has been
shown to positively regulate transcriptional activities of
Ets1 and Ets2. [76,77].
Binding sites of the transcription factors OCT1, MZF1,
PPARg, PLZF, ETS, and HMGIY were found to be overrep-
resented in promoters of genes induced by overexpression
of c-Myc. Their own gene expression, however, was
unchanged. One explanation for this observation might
be their regulation on the protein level. Nevertheless,
some of these transcription factors seem to participate
also in the Myc tumorigenic phenotype.
Conclusion
Taken collectively, after transcription profiling of lung
adenocarcinomas of female c-Myc-transgenic mice we
were able to describe the c-Myc regulatory gene network in
silico. By using positional weight matrices (PWMs), which
is the most widely used method for recognition of tran-
scription factor binding sites, we identified different
mechanisms by which c-Myc putatively mediates its tum-
origenic actions (see Figure 2):
1) Putative direct actions in part in cooperation or compe-
tition with other transcription factors (Figure 5).
2) Putative indirect c-Myc actions, mediated by transcrip-
tion factors transcriptionally induced by overexpression
of c-Myc (Figure 6).
3) Putative indirect c-Myc actions, mediated by transcrip-
tion factors regulated by overexpression of c-Myc on the
protein level or mediated by as yet unknown mechanisms
(Figure 7).
Thus, our in silico description of the c-Myc regulatory
gene network has yielded already known and also many
novel putative direct and indirect targets of c-Myc. It pro-
vides some insights into how tumorigenesis is caused by
deregulated c-Myc, a prevalent finding in human cancers.
Methods
Tissue samples
c-Myc-transgenic female mice displayed morphological
alterations with varying degree of nuclear atypia, such as
bronchiolo-adenomas and bronchiolo-adenocarcinomas.
Thus, different stages of malignant transformation of alve-
olar epithelium were observed. In the non-transgenic con-
trol animals no abnormalities in lung tissue was detected
with the exception of a single animal which showed a
slight focal interstitial mononuclear cell infiltration.
Gene expression studies
For gene expression analysis, either c-Myc-transgenics or
non-transgenic controls were pooled such that 4 pools of
4 mice per group could be analyzed. Each pool was ana-
lysed in one microarray experiment. Only aliquots of indi-
vidual RNA isolations were pooled, thus allowing
measurement of selected genes by quantitative RT-PCR
amongst all individual animals. Therefore, RNA was iso-
lated from lung tissue of each individual animal, and
identical amounts of RNA from 4 individuals of one
group were pooled.BMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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Transcriptome analysis was done according to the manu-
facturer's recommendation (Affymetrix GeneChip®
Expression Analysis Technical Manual (Santa Clara, CA)),
using the GeneChip® Test Arrays and GeneChip® Mouse
Genome 430 2.0. The frozen lung tissues (10–15 mg)
were disrupted and homogenized using a rotor-stator
homogenizer, and total RNA was isolated from the tissues
using the RNeasy total RNA isolation kit (QIAGEN). RNA
of individual samples was pooled as described above, and
a second cleanup of isolated RNA was done using the
RNeasy Mini Kit (QIAGEN). RNA was checked for quan-
tity, purity, and integrity of the 18S and 28S ribosomal
bands by capillary electrophoresis using the NanoDrop
ND-1000 and the Agilent 2100 Bioanalyzer.
8 μg of total RNA were used as starting material to prepare
cDNA. Synthesis of double-stranded cDNA was done with
the GeneChip®  one-cycle cDNA Kit (Affymetrix). The
cleanup of double-stranded cDNA was done using the
GeneChip® Sample Cleanup module (Affymetrix).
12 μl of cDNA solution were used for in vitro transcrip-
tion. The in vitro transcription was conducted with the
GeneChip®  IVT Labeling Kit (Affymetrix). The total
amount of the reaction product was purified with the
GeneChip® Sample Cleanup module (Affymetrix). Puri-
fied cRNA was quantified and checked for quality using
the NanoDrop ND-1000 and the Agilent 2100 Bioana-
lyzer. Purified cRNA was cleaved into fragments of 35–
200 bases by metal-induced hydrolysis. The degree of frag-
mentation and the length distribution of the fragmented
biotinylated cRNA were checked by capillary electro-
phoresis using the Agilent 2100 Bioanalyzer.
10 μg of biotinylated fragmented cRNA were hybridized
onto the GeneChip® Mouse Genome 430 2.0 array accord-
ing to the manufacturer's recommendation. The hybridi-
zation was performed for 16 hours at 60 rpm and 45°C in
the GeneChip®  Hybridization Oven 640 (Affymetrix).
Washing and staining of the arrays was done on the Gene-
Chip® Fluidics Station 400 (Affymetrix) according to the
manufacturer's recommendation. The antibody signal
amplification, washing, and staining protocol (Affyme-
trix) was used to stain the arrays with streptavidin R-phy-
coerythrin (SAPE; Invitrogen, USA). To amplify staining,
SAPE solution was added twice with a biotinylated anti-
streptavidin antibody (Vector Laboratories, CA) staining
step in between.
The arrays were scanned using the GeneChip® Scanner
3000. Scanned image files were visually inspected for arti-
facts and then analyzed, each image being scaled to the
same target value for comparison between chips. The
GeneChip® Operating Software (GCOS) was used to con-
trol the fluidics station and the scanner, to capture probe
array data, and to analyze hybridization intensity data.
Default parameters provided in the Affymetrix data analy-
sis software package were applied for analysis.
After scanning, the GeneChip®  Operating Software
(GCOS; version 1.1) generated the expression data for
every single chip.
As detailed by the manufacturer, expression of a gene is
corroborated by a set of 11 pairs of 25-oligomer. Next to
perfect sequence matches, deliberate mismatches which
differ by one base only in the middle of the oligomer are
introduced to confirm hybridization products. A statisti-
cal expression algorithm within the GeneChip® Operating
Software (GCOS) calls on multiple perfect sequence
matches and mismatches to determine the presence [a
detection call "present" (P) or "absent" (A)] and abun-
dance (a signal value) of an individual transcript. The
detection (absolute information) and the signal (numeri-
cal values) are calculated independently.
To determine whether a gene is "significantly present", the
average signal value (Signal-Avg) and the standard devia-
tion [Stdev and Stdev(%)] were calculated using Affyme-
trix®  Data Mining Tool Software (version 3.1) and
Microsoft®  Excel 2003. Additionally, the number of
"present" calls (P-count) for each gene in four replicates
was determined.
Criteria applied for a "significantly present" gene were, for
example: average signal value ≥ 100, and all four "detec-
tion calls" must be "present" (P-count).
Multiple data from replicates were evaluated and com-
pared using statistical analysis with the Affymetrix® Gene-
Chip® Operating Software (GCOS) and Data Mining Tool
(DMT). The average and standard deviation statistics
within Affymetrix®  DMT were used to summarize the
expression level (the signal values) for each transcript
across the replicates. The unpaired t-test and comparison
ranking were used to determine the direction and signifi-
cance of change in a transcript's expression level between
sets of replicates. Fold change values were calculated as
the ratio of the average expression levels for each gene
between c-Myc-transgenic animals and the correlating
control experiment.
To extract genes with significantly altered expression, a
comparison between groups of animals was conducted
using the GeneChip® Operating Software (GCOS). A com-
parison analysis was conducted for the female group
within the c-Myc-transgenic line: transgenic versus non-
transgenic strains.BMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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For the comparison analysis, it was ensured that the scale
factors for the compared chips did not differ by a factor
larger than 3. The result of a single analysis between two
different arrays was reported for each gene as "increase"
(I) or "decrease" (D), and the change in signal intensity
was determined as the signal logarithm ratio (log2ratio).
In this study, with four replicates per group, 16 compari-
son analyses (4 transgenic versus 4 non-transgenic) were
conducted. Comparison ranking analysis was additionally
done to study concordance between "increase calls" (I) or
"decrease calls" (D) for replicates (this is counting the
number of "I-calls" and "D-calls" out of 16).
The unpaired one-sided t-test converting the p-value to a
two-sided p-value was used to determine the direction
and significance of change in a transcript's expression
level (Data Mining Tool, version 3.1). Signal values of
each group were used as basis for calculation, with the
original p-value cutoff determined to be 0.05.
Comparing different groups, a "fold change" (FC) was cal-
culated, which is the ratio between the average signal val-
ues of groups to be compared. Ratios ≤ 1 were recalculated
to give negative numbers whose magnitude resembles the
extent of repression (for example: ratio of 0.5 was changed
to -2).
To select genes in the c-Myc experiments, the following
criteria were applied for the comparison conducted:
1. For induced genes
m the average signal value of the "treatment" had to be
higher than 100
m 4 P-calls had to be in the 4 "treatment" arrays
m the fold change had to be 2.0 or higher (ratio of average
signal values)
m the result of the t-test had to be an "Up"-change call (p-
value < 0.05) (based on single signal values of 4 repli-
cates)
m there had to be more than 13 (out of 16) induced calls
in the comparison ranking
2. For repressed genes
m the average signal value of the "control" had to be
higher than 100
m 4 P-calls had to be in the 4 "control" arrays
m the fold change had to be -2.0 or less (ratio of average
signal values)
m the result of the t-test had to be a "Down"-change call
(p-value < 0.05) (based on single signal values of 4 repli-
cates)
m there had to be more than 13 (out of 16) decrease calls
in the comparison ranking
Applying these criteria as detailed above, probe sets signif-
icantly altered in expression were selected. In a few cases,
two or more of these "probe sets" were targeting the same
gene.
To prevent reiterations, the following criteria were applied
and only one "probe set" per gene was selected:
1. Primarily, "probe sets" not specific for one transcript
were eliminated (indicated in the Probe Set ID by an addi-
tional letter, e.g. 1370470_x_at).
2. In case all probe sets were specific (Probe Set IDs with-
out an additional letter, i.e. 138520_at) or all were not
specific, those with higher signal values were selected.
Real-time PCR
Real-time PCR measurement was done with the LightCy-
cler® (Roche Diagnostics, Penzberg, Germany). RNA was
treated with Dnase and purified with RNeasy Mini Kit.
Quality of purified RNA was analyzed in a denaturating
Agarose gel. Reverse transcription (RT) was performed
with 2 μg of RNA using Omniscript (Qiagen), RNase
inhibitor and hexamers (Promega) in a final volume of 20
μl. RT reactions were diluted 1:4 and 2 μl was used for
Real-time PCR. SYBR® Green I was used as a fluorescent
dye to determine the amplified PCR products after each
cycle. The lengths of PCR products were checked in gel
electrophoresis. PCR primers were synthesized by Invitro-
gen (Karlsruhe, Germany). At the end of each extension
phase fluorescence was observed and used for quantitative
measurements within the linear range of amplification
yielding calculated concentrations as relative units. Exact
quantification was achieved by serial dilution with cDNA
produced from total RNA extracts using 1:5 or 1:3 dilution
steps, depending on the expression level of the gene. Six
runs were necessary to measure expression of the genes in
all samples. For comparability of the six independent
runs, standards were used, which were identical sample
pools for all six runs. The standardized sample values for
each gene of interest were divided through the standard-
ized values of the housekeeping gene. As housekeeping
gene, Ppib (peptidylprolyl isomerase B; cyclophilin B)
was used.
Sequence retrieval
The UCSC Genome Browser [78] was used to extract the
promoter regions of regulated genes and promoterBMC Systems Biology 2008, 2:46 http://www.biomedcentral.com/1752-0509/2/46
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regions of control genes with no change in expression.
Exclusively promoters of genes which are RefSeq anno-
tated were extracted. The beginning of the first exon which
also comprises the 5'UTR was considered to be a tentative
TSS (transcription start site) [79]. 1000 bp upstream and
100 bp downstream of TSS were extracted, respectively.
The choice of these regions was based on previous obser-
vations that c-Myc frequently binds to the regions having
a distance of up to 1000 bps from the TSS [80,81]. It must
be mentioned, however, that binding of c-Myc has also
been proved to occur in the first intron of c-Myc target
genes [82].
Process of promoter analysis
The most widely used method for recognition of tran-
scription factor binding sites is the application of posi-
tional weight matrices (PWMs) [34] TRANSFAC®
Professional rel. 10.1 is the largest collection of weight
matrices for eukaryotic transcription factors [83,84] (BIO-
BASE GmbH, Wolfenbüttel, Germany). Here, the TRANS-
FAC®-integrated MATCH™ algorithm was employed,
calculating scores for the matches by applying the so-
called information vector [85]. The matrix profile
"vertebrates_minSUM_highQual" was used. Default cut-
off values for matrix similarity were used, whereas the cut-
off values for core similarity were always set to 0.75. The
matrix similarity cutoff is a score that describes the quality
of a match between a matrix and an arbitrary part of the
input sequences. In addition, only those matches which
score higher than or equal to the matrix similarity thresh-
old appear in the output. The number of transcription fac-
tor binding sites identified in the analyzed promoter set
was compared to the number of transcription factor bind-
ing sites identified in a control promoter set [promoters of
100 selected genes which were not regulated at all in all
four different groups]. The list of non-regulated genes was
prepared after applying criteria described below and was
included in Additional file 2.
Selection of genes suitable as control promoters
For analysis of promoters of significantly altered genes,
promoters of genes with no change in expression were
selected. To do so, genes needed to be expressed with a sig-
nal value above 100, and the detection call of all 4 repli-
cates had to be present. At the same time, the fold change
must not be greater than 1.1 nor less than -1.1, the change
direction, which is the result of the t-test with a p-value
greater than 0.5, had to have a "None" call, and of the 16
comparison analyses conducted, less than five were
allowed to have an "Induction" or a "Down" call. These
criteria, applied to each comparison separately, in each
case had to be true for all comparisons at the same time.
They are summarized as follows:
m the average signal value of the "treatment" had to be
higher than 100
m 4 P-calls had to be in the 4 "treatment" arrays
m the fold change had to be between the range 1.1 and -
1.1 (ratio of average signal values)
m the result of the t-test had to be a "None"-change call
m there had to be less than 5 (out of 16) induced calls in
the comparison ranking
Applying these criteria for c-Myc as detailed above, 164
probe sets for genes with almost no change in expression
were selected. In addition, 100 genes with a Transcript
RefSeq number were selected to be used to extract pro-
moter sequences for controls (Additional file 2).
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